Best of the Blog: IN VIVO, September 2009
Our favorite posts from The IN VIVO Blog about issues not covered elsewhere in this month's IN VIVO. (See the original postings for free at http://invivoblog.blogspot.com/).
You may also be interested in...
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
Firm stresses Phase III efficacy results will pass muster with FDA.